Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParSGX:H02 -1.05%95 FCF Yield % is 1.54 as of Aug. 05, 2026, which is 26% below its 10-year median of 2.07. GuruFocus rates SGX:H02 with a GF Score™ of 95/100 and a GF Value™ of S$11.90 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Haw Par ranks better than 55.41% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Haw Par's Trailing 12-Month Free Cash Flow is S$55.0 Mil, and Market Cap is S$3,588.4 Mil. Therefore, Haw Par's FCF Yield % for today is 1.54%.
The historical rank and industry rank for Haw Par's FCF Yield % or its related term are showing as below:
SGX:H02'
s FCF Yield % Range Over the Past 10 Years
Min: 0.54 Med: 2.07 Max: 6.37
Current: 1.54
During the past 13 years, the highest FCF Yield % of Haw Par was 6.37%. The lowest was 0.54%. And the median was 2.07%.
SGX:H02's FCF Yield % is ranked better than 55.41% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.73
vs SGX:H02: 1.54
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Haw Par FCF Yield % Related Terms
Haw Par FCF Yield % Historical Data
* Premium members only.
The historical data trend for Haw Par's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Haw Par's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (SGX:H02) has a FCF Yield % of 1.54 as of Aug. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Haw Par and its competitors. This is 26% below median its historical median of 2.07. Over the past decade, Haw Par's FCF Yield % has ranged from 0.54 to 6.37. According to the industry distribution chart, Haw Par ranks #449 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Haw Par's FCF Yield % too high?
Haw Par's current FCF Yield % of 1.54 is 26% below median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 6.37. The Drug Manufacturers industry median FCF Yield % is 0.73. Haw Par's value of 1.54 is 111% above this industry median. Based on the distribution chart, Haw Par ranks #449 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Haw Par has a GF Score™ of 95/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's FCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #449 out of 1007 companies for FCF Yield %. This puts Haw Par in the upper half of its industry. The industry median FCF Yield % is 0.73. Haw Par's value of 1.54 is 111% above this benchmark. Historically, Haw Par's own FCF Yield % has ranged from 0.54 to 6.37 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 0.73, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.73, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current FCF Yield % of 1.54 is 111% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current FCF Yield % is 1.54, which is 26% below median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (SGX:H02) is currently considered Significantly Overvalued. The stock's GF Value™ is S$11.90, compared to a current price of S$16.04 — trading 34.8% above its estimated fair value. The current FCF Yield % is 1.54, which is 26% below median its 10-year median of 2.07 and 111% above the Drug Manufacturers industry median of 0.73. Haw Par's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Haw Par (SGX:H02), the current FCF Yield % is 1.54 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (SGX:H02) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of S$16.04 is trading 34.8% above its estimated GF Value™ of S$11.90.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for SGX:H02:
FCF Yield %: 1.54 (26% below median its 10-year median of 2.07)
GF Value™: S$11.90 vs. price of S$16.04 (34.8% above fair value)
Industry Position: 111% above the Drug Manufacturers median (#449 of 1007)
No single metric tells the full story. See the SGX:H02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
95GF Score
Get the complete analysis for SGX:H02
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:H02 has been successfully added to your 
